Skip to main content
Clinical Trials/NCT00768820
NCT00768820RecruitingPhase 4

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

The Chaim Sheba Medical Center1 site in 1 country400 target enrollmentStarted: May 1, 2001Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Sponsor
Enrollment
400
Locations
1
Primary Endpoint
Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments

Study Overview

Brief Summary

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •chromosomal deletion proven by FISH examination

Exclusion Criteria

  • Not provided

Arms & Interventions

1

Experimental

Intervention: methylphenidate, fluoxetin, risperidone (Drug)

Outcomes

Primary Outcomes

Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments

Time Frame: 2 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
The Chaim Sheba Medical Center
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Prof. Doron Gothelf

Principal Investigator

The Chaim Sheba Medical Center

Study Sites (1)

Loading locations...

Similar Trials